Introduction
In the realm of anthropology, particularly within the subfield of feminist economic anthropology, the intersection of sex and money reveals how intimate aspects of human life are commodified under capitalist patriarchy. This essay explores the emergence of Female Sexual Dysfunction (FSD) as a diagnostic category, prompted by the cultural question following Viagra’s 1998 approval: “Where is the Viagra for women?” This query not only highlighted a perceived gap in biomedical interventions for women’s sexuality but also intensified commercial and clinical focus on conditions like Hypoactive Sexual Desire Disorder (HSDD). Historically, women’s sexuality has been medicalised, from Victorian-era diagnoses of hysteria and nymphomania to contemporary framings of low desire as an “unmet medical need” (Tiefer, 2006). Media, pharmaceutical industries, and clinical discourses have intertwined to promote this narrative, often obscuring social and economic influences.
This is not a novel phenomenon; it echoes a long history of pathologising women’s bodies under patriarchal structures. The thesis of this exploratory paper argues that FSD is not merely a biomedical discovery but a socially and economically constructed category, shaped by pharmaceutical networks, clinical expertise, and cultural norms. Drawing on feminist economic anthropology, it examines how lived sexual experiences—representing use value—are transformed into diagnostic and pharmaceutical markets, embodying exchange value, thereby masking underlying social conditions that influence desire. Briefly, this mirrors the marketing of erectile dysfunction (ED) treatments, which frame penetrative sex as the standard of male virility and authority, reinforcing heteronormative capitalist patriarchy. Through this lens, the essay analyses FSD’s construction, applies anthropological theories, imagines ethnographic approaches, and reflects on broader implications.
How FSD is Constructed in Dominant Discourse
The dominant discourse surrounding Female Sexual Dysfunction (FSD) frames it primarily as a biomedical issue, drawing on psychiatric classifications and neurobiological models. The Diagnostic and Statistical Manual of Mental Disorders (DSM) categorises women’s sexual problems into domains such as desire, arousal, orgasm, and pain, treating them as individual bodily malfunctions akin to mechanical failures (Tiefer, 2006). This neurobiological framing emphasises sexual response systems, distinguishing “function” from “dysfunction” through physiological metrics, often derived from animal studies or genital physiology research. For instance, it posits that sexual problems stem from disruptions in neurotransmitter pathways or hormonal imbalances, ignoring relational or contextual factors. Tiefer (2006) highlights the historical continuity of this medicalisation, noting how it extends from 19th-century notions of hysteria to modern pharmaceutical-driven narratives, where women’s sexuality is reframed as a treatable condition rather than a product of social inequalities.
Furthermore, FSD is actively constructed as a disease through pharmaceutical strategies that create an “epidemic” narrative. Prevalence statistics, such as those claiming 43% of women experience sexual dysfunction, are leveraged to build markets by portraying it as a widespread “unmet medical need” (Moynihan, 2003). This language serves as a market-building tool, transforming everyday sexual dissatisfaction into a pathological condition requiring intervention. Moynihan (2003) describes this as “disease-mongering,” where pharmaceutical companies, through media campaigns and funded research, exaggerate the scope of FSD to justify drug development. For example, following Viagra’s success, industry efforts shifted to women, promoting off-label uses and new compounds despite limited evidence. This process is not passive discovery but deliberate category production, aligning with capitalist interests in lifestyle drugs.
Clinical networks further solidify FSD’s construction through industry-funded conferences and expert panels that shape diagnostic criteria. Continuing Medical Education (CME) events, often subsidised by pharmaceutical firms, influence how clinicians define and treat FSD, co-producing drugs and diagnoses (Jin, 2015). The approval of flibanserin for HSDD exemplifies this, where clinical trials and consensus statements from funded experts framed low desire as a neurochemical deficit amenable to pharmacological solutions. Jin (2015) outlines how such framing prioritises drug-based treatments, with researchers acting as intermediaries between companies and consumers, thereby legitimising FSD as a medical entity. However, this raises concerns about conflicts of interest, as many presenters at FSD conferences disclose ties to industry, potentially biasing definitions toward marketable outcomes.
Additionally, pharmaceutical spillover effects complicate the discourse, as medications like Selective Serotonin Reuptake Inhibitors (SSRIs) induce sexual dysfunction as an underrecognised side effect, leading to layered interventions (Jing and Straw-Wilson, 2016). This creates a cycle where one drug’s adverse effects necessitate another, further entrenching biomedical solutions. Jing and Straw-Wilson (2016) discuss how SSRI-induced dysfunction adds medical complexity, yet dominant narratives frame these as individual issues rather than systemic problems within pharmacocentric healthcare. Overall, this construction obscures social contexts, such as gender norms or economic pressures, by prioritising bodily “fixes” under capitalist patriarchy, where women’s desire is commodified similarly to men’s virility in ED marketing, which upholds penetrative sex as a marker of masculine authority.
Feminist Economic Anthropology Analysis
Feminist economic anthropology provides a critical framework for understanding FSD as a product of capitalist patriarchy, where women’s sexuality is structured through systems of exchange. Gayle Rubin’s seminal work on the “traffic in women” illustrates how kinship and heterosexuality organise gendered power relations, treating women as exchangeable commodities within patriarchal economies (Rubin, 1975). Applied to FSD, this theory reveals how sexual experiences are translated into biomedical categories for market exchange. Rubin (1975) argues that women’s sexuality is not innate but shaped by social structures that prioritise male dominance; similarly, FSD converts intimate desires into diagnostic labels, enabling pharmaceutical profits while reinforcing heteronormative norms.
Central to this analysis is the distinction between use value and exchange value. Use value refers to the embodied, relational aspects of sexuality—pleasure, intimacy, and contextual factors like emotional bonds or stress (Tiefer, 2006). In contrast, exchange value manifests in measurable forms such as prevalence rates, diagnostic criteria, and drug markets, where “unmet needs” become commodities (Moynihan, 2003). This transformation obscures social conditions; for instance, women’s low desire might stem from labour exhaustion or gender inequalities, yet biomedical framing renders it legible only as a marketable dysfunction. Arguably, this process exemplifies capitalist patriarchy, commodifying women’s bodies much like ED treatments do for men, by tying virility to penetrative performance and economic productivity.
Neoliberal ideologies exacerbate this, positioning sexual health as an individual responsibility for optimisation within assumed heterosexual frameworks. The “female Viagra” logic embeds couple-based heteronormativity, portraying women as self-managing consumers who must enhance desire to fulfil relational roles (Jin, 2015). This ignores structural critiques, where feminist scholars highlight how sex education gaps, gender norms, violence, trauma, and economic labour shape sexual distress (Tiefer, 2006). Biomedical models remove these from view, focusing on personal “deficits” rather than systemic issues, thus perpetuating patriarchal control over women’s sexuality.
Indeed, a structural feminist critique reveals that FSD’s framing distracts from broader inequalities. Factors like inadequate sex education or caregiving burdens, often tied to gendered labour divisions, contribute to sexual dissatisfaction, yet are sidelined in favour of pharmaceutical solutions (Rubin, 1975). This analysis, therefore, underscores how intimacy is alienated into exchange value, aligning with Rubin’s (1975) view of sexuality as economically mediated.
Ethnographic Imagination
An ethnographic approach would illuminate the lived realities behind FSD’s construction, bridging epidemiological claims with social contexts. Imagine studying clinics where DSM checklists diagnose women, observing how clinicians apply biomedical categories amid patients’ narratives of relational stress or trauma. Fieldwork at CME conferences could reveal pharmaceutical influence, tracking how funded panels shape discourse and obscure conflicts of interest (Moynihan, 2003). Furthermore, engaging women’s lived experiences—through interviews on desire, exhaustion, and relationships—would highlight discrepancies between institutional labels and personal realities.
Online communities discussing drugs and side effects, such as SSRI impacts, offer another site, showing how users negotiate biomedical framings (Jing and Straw-Wilson, 2016). The key question is whether individuals experience themselves through FSD categories or if these are imposed institutionally. Ethnography would reveal gaps between “epidemic” narratives and everyday lives, where social factors like capitalist labour demands overshadow physiological “dysfunctions” (Tiefer, 2006). Typically, such studies expose how power dynamics in healthcare commodify sexuality, providing nuanced insights into resistance and agency.
Conclusion
In summary, Female Sexual Dysfunction emerges as a co-produced cultural and economic category, shaped by biomedical, pharmaceutical, and normative forces rather than objective medical fact. Feminist economic anthropology, drawing on Rubin’s (1975) political economy of sex, illustrates how lived intimacy (use value) is transformed into marketable diagnostics (exchange value) within capitalist patriarchy. This obscures social determinants, mirroring ED marketing’s emphasis on penetrative sex as male authority.
The main insight is that such translations prioritise profit over holistic understanding, yet this does not reject medicine entirely. Instead, it questions how sexual experiences become subsumed under market logic and diagnostic authority, urging a reevaluation of women’s sexuality beyond commodification. Ultimately, this perspective encourages anthropological inquiries that centre lived realities, fostering more equitable approaches to sexual health.
References
- Jin, L. (2015) Flibanserin for Treating Low Sexual Desire in Women. JAMA.
- Jing, E. and Straw-Wilson, K. (2016) Sexual Dysfunction in SSRIs and Potential Solutions. Mental Health Clinician.
- Moynihan, R. (2003) The Marketing of a Disease: Female Sexual Dysfunction. BMJ.
- Rubin, G. (1975) “The Traffic in Women: Notes on the Political Economy of Sex.” Available at: https://www.yale.edu/gender/trafficking_in_women.pdf (accessed [date]).
- Tiefer, L. (2006) Female Sexual Dysfunction: A Case Study of Disease Mongering and Activist Resistance. PLOS Medicine.
